The only late-stage human data on thymosin beta-4 are for eye drops, and they are mixed

Published 26 October 2026 · REVIVE LAB UAE Research Desk · 5 min read
RegeneRx Biopharmaceuticals developed synthetic full-length thymosin beta-4 in several formulations: RGN-259 as a preservative-free eye drop, RGN-137 as a topical gel for skin wounds, and RGN-352 as an injectable for cardiac indications. The eye programme went furthest: phase 2 trials and then the phase 3 ARISE trials in dry eye disease and the SEER trials in neurotrophic keratopathy, through the 2010s and into the 2020s. Results were mixed, with some endpoints met and others not, and no product has been approved. The injectable programme stopped after phase 1. None of this concerns the 17-residue fragment.

The programmes

Dry eye: several hundred patients across the ARISE trials, with sign and symptom endpoints; some trials reported significant effects on individual signs and others did not reach their primary endpoints. Neurotrophic keratopathy, a rare corneal condition: small SEER trials reporting complete healing in a proportion of patients. Skin wounds: phase 2 in epidermolysis bullosa and pressure ulcers with modest results. Cardiac: phase 1 safety only.

The company has pursued partnerships rather than filing for approval.

What the data show

That full-length thymosin beta-4 applied to the eye surface is tolerated and may help corneal healing in some patients, with the dry eye evidence inconsistent. This is the sum of late-stage human evidence for the molecule. It was generated with the 43-residue protein, topically, in eye conditions.

It is honest, limited and specific.

Why it does not transfer

A different molecule, a different route, a different tissue. Nothing in the eye trials bears on a fragment of the protein given by any other route for any other purpose, and this page does not suggest otherwise.

The BPC-157 + TB500 blend is supplied by REVIVE LAB UAE for laboratory research use only, with identity by mass spectrometry and purity by HPLC for each component of the batch. It is not for human or veterinary use, and no dosing, administration or protocol guidance is provided.

What it costs

FormatStrengthPriceAvailability
BPC-157 + TB500 Pack5 mg + 5 mgAED 510In stock

Delivery is AED 40 flat and free on orders over AED 700. Payment is cash on delivery anywhere in the UAE, or USDT (TRC20) in advance, which takes 5% off the order total.

Frequently asked

The programmes?

Dry eye: several hundred patients across the ARISE trials, with sign and symptom endpoints; some trials reported significant effects on individual signs and others did not reach their primary endpoints. Neurotrophic keratopathy, a rare corneal condition: small SEER trials reporting complete healing in a proportion of patients. Skin wounds: phase 2 in epidermolysis bullosa and pressure ulcers with modest results. Cardiac: phase 1 safety only.

Does REVIVE LAB UAE provide dosing guidance?

No. REVIVE LAB UAE supplies research materials and provides no dosing, administration or protocol guidance of any kind. Every product is sold for laboratory research use only and is not for human or veterinary consumption.

How fast is delivery in the UAE?

Stock is held in Dubai. An order confirmed before 4 PM Dubai time is dispatched the same working day, reaching Dubai and Abu Dhabi the same day and the remaining emirates within 24 hours. Delivery is AED 40 flat and free over AED 700.

BPC-157 + TB500 Pack — in stock, dispatched from Dubai
HPLC-verified, lot certificate on every carton, 24-hour delivery nationwide. Browse the catalogue → All peptides UAE

Related reading

Supplied for laboratory research use only. Not for human or veterinary consumption. REVIVE LAB UAE provides no dosing, administration or protocol guidance.